Aliqopa (Copanlisib)
- Medicine Name: Aliqopa
- Generic Name: Copanlisib
- Dosage Form & Strength: For injection: 60 mg as a lyophilized solid in single-dose vial
- Manufactured By: Bayer Corporation
- Severe, including fatal, infections occurred in patients treated with Copanlisib monotherapy. Monitor patients for signs/symptoms of infection and withhold Copanlisib 60mg injection for Grade 3 and higher infection.
- Severe pneumocystis jiroveci pneumonia (PJP) may emerge in patients taken treatment with Aliqopa monotherapy. Prior to initiating therapy, consider PJP prophylaxis for individuals at risk.
- Grade 3/4 hyperglycemia (blood glucose 250 mg/dL or higher) and severe hyperglycemic events may occur in patients treated with Aliqopa monotherapy. Achieve optimal blood glucose control prior to starting each infusion. Withhold, reduce dose, or discontinue therapy depending on the severity and persistence of hyperglycemia.
- Grade 3 hypertension (systolic 160 mmHg or higher or diastolic 100 mmHg or higher) occurred in patients treated with Aliqopa monotherapy. Monitor BP pre- and post-infusion. Withhold, reduce dose, or interrupt aliqopa 60 mg injection depending on the severity and persistence of hypertension.
- Non-infectious pneumonitis emerged in patients treated with Copanlisib monotherapy. Withhold this drug and conduct a diagnostic evaluation of a patient who is experiencing pulmonary symptoms such as dyspnea, cough, hypoxia, or interstitial infiltrates on radiologic exam.
- Grade 3/4 neutropenia may occur in patients treated with injection aliqopa 60 mg. Severe neutropenic events may occur. Monitor blood counts at least on a weekly basis during therapy. Withhold, reduce dose, or interrupt inj aliqopa 60 mg on behalf of severity and persistence of neutropenia.
- Based on outcomes in animals and its mechanism of action, this medication can cause fetal harm if received by a pregnant woman. Respective women of reproductive age and men with women partners of reproductive age should use apt contraception during therapy and for at least 30 days after the final dose.
What documents are required to import ALIQOPA to India?
ALIQOPA (copanlisib) injections can be imported by patients or government hospitals on the name of the patients only.
The following documentation required in order to import the product:
- Valid prescription from a qualified doctor.
- Patient’s diagnostic reports
- Patient’s ID proof (issued by the government of India)
How will the order be confirmed?
The order will be confirmed only after the receipt of:
- Valid prescription from a doctor
- Import permit if applicable
Is ALIQOPA available in India?
ALIQOPA (copanlisib injection) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.
Urgent Meds facilitates the import of cancer medicines on the named patient supply (NPS). Urgent Meds is a facilitator providing input on:
- Availability in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, and Pune, etc.)
- Medicine Price
- Finding genuine and reliable sources from Canada, Europe, USA, and Australia
- Ensuring 100% transparency
ALIQOPA can be made available to patients, doctors, and hospitals at Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, Pune, and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.
Urgent Meds can facilitate the supply of ALIQOPA (prescription medicines) to all locations in the world and in India after fulfilling the legal requirements (if applicable).
Please contact +1-647-818-4196 or write to us at info@urgentmeds.in for ALIQOPA injection price in India.
We take guarantee of quality and delivery anywhere in the world as per the buyer’s requirements.
Urgent Meds is proficient in sourcing ALIQOPA(Medicines from around the world and has the capability to supply it. We offer global access to the best available treatment for our customers worldwide.
Urgent Meds is committed to dispensing any valid prescription promptly. All prescriptions are dispensed and verified by registered pharmacists and are dispatched only to the patient’s address from New Delhi, India. Your health and well-being are our top priorities.
What is the Generic Name for the trade name drug Aliqopa®?
Copanlisib is the generic name for the trade name drug Aliqopa®.
What is the Manufacturer Name of Aliqopa®?
Aliqopa® is manufactured by Bayer HealthCare Pharmaceuticals Inc.
Is Aliqopa® approved by the FDA?
Yes, Aliqopa® is approved by the FDA. Date of approval: September 14, 2017.
What is the dosage and form of Aliqopa® supplied?
Aliqopa® is supplied for injection: 60 mg as a lyophilized solid in a single-dose vial for reconstitution for intravenous administration.
What are the most common side effects due to Aliqopa®?
The most common side effects due to Aliqopa® include lower respiratory tract infections, hyperglycemia, hypertension, diarrhea, decreased general strength and energy, nausea, leukopenia, neutropenia, and thrombocytopenia.
Can I take Aliqopa if I’m pregnant or breastfeeding?
You must have a negative pregnancy test prior to starting Aliqopa. Avoid breastfeeding while using this medication and for at least 30 days after the final dose.
How much does Aliqopa® cost in India?
The cost of Aliqopa in India is reasonable and can vary. In order to procure this follicular lymphoma medication authentically, you can call or WhatsApp +1-647-818-4196 or send an email to info@urgentmeds.in.
What are the storage conditions of Aliqopa®?
Vials of Aliqopa must be refrigerated at a temperature of 2°C to 8°C (36°F to 46°F).
Contact Patient Support
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
Disclaimer
All Trademarks and Brands that appear on the website belong to their respective owners and indianpharmanetwork does not lay any claim on them we only provide Information.